Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization
- 31 July 1997
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 30 (1) , 149-156
- https://doi.org/10.1016/s0735-1097(97)00110-1
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)The American Journal of Cardiology, 1995
- Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable anginaJournal of the American College of Cardiology, 1994
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- Percutaneous transluminal coronary angioplasty for unstable anginaThe American Journal of Cardiology, 1991
- Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplastyAmerican Heart Journal, 1989
- Aspirin, Heparin, or Both to Treat Acute Unstable AnginaNew England Journal of Medicine, 1988
- Aspirin and Dipyridamole in the Prevention of Re-Stenosis after Percutaneous Transluminal Coronary AngioplastyNew England Journal of Medicine, 1988
- Aspirin, Sulfinpyrazone, or Both in Unstable AnginaNew England Journal of Medicine, 1985
- Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable AnginaNew England Journal of Medicine, 1983